IGF-1 LR3

IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1) with an arginine substitution and extended sequence. It has been studied in cell and animal models for its effects on muscle growth, tissue repair, and skeletal development.

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analogue of human IGF-1, engineered with an 83-amino acid sequence that includes an N-terminal extension of 13 amino acids and a substitution of arginine for glutamine at the third position. This modification significantly reduces its affinity for IGF-binding proteins (IGFBPs), which normally sequester endogenous IGF-1 and restrict its bioavailability. Consequently, IGF-1 LR3 maintains a dramatically extended half-life—approximately 20 to 30 hours compared to the minutes-long half-life of natural IGF-1—allowing it to exert sustained systemic effects.

It functions primarily by binding to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase, initiating an autophosphorylation cascade that activates the PI3K/Akt and MAPK/ERK signaling pathways. At the cellular level, the activation of the PI3K/Akt pathway is central to its anabolic and anti-catabolic profile. This signaling cascade triggers the activation of the mammalian target of rapamycin (mTOR) complex 1, which acts as a master regulator of protein synthesis and cellular growth. By stimulating ribosomal biogenesis and mRNA translation, IGF-1 LR3 facilitates accelerated myofibrillar protein synthesis.

Simultaneously, the molecule exerts anti-catabolic pressure by inhibiting the FoxO transcription factors; normally, these factors promote the expression of atrogin-1 and MuRF-1, which are E3 ubiquitin ligases responsible for muscle protein degradation. By sequestering these ligases, IGF-1 LR3 effectively blunts muscle proteolysis and supports positive nitrogen balance. Beyond protein accretion, IGF-1 LR3 modulates metabolic flux and body composition through potent effects on adipose tissue and glucose homeostasis. It functions as a metabolic switch, enhancing insulin sensitivity in skeletal muscle by promoting the translocation of GLUT4 glucose transporters to the plasma membrane, thereby increasing glucose uptake for glycogenesis.

In adipose tissue, IGF-1 LR3 facilitates lipolysis and inhibits adipogenesis through the downregulation of genes associated with lipid storage. Furthermore, it influences satellite cell activity; by stimulating the proliferation and differentiation of these myogenic stem cells, the compound increases the myonuclear domain, enabling greater long-term muscle hypertrophy and the repair of micro-trauma in connective and muscular tissues. It is important to distinguish the specific pharmacodynamics of IGF-1 LR3 from other hormonal pathways; it does not directly bind to the androgen receptor (AR), nor is it subject to enzymatic conversion via aromatase (estrogen) or 5-alpha reductase (DHT).

Unlike growth hormone (GH), which must undergo hepatic conversion into IGF-1 to exert many of its tissue-building effects, IGF-1 LR3 is a direct-acting ligand that bypasses the need for the GH-IGF-1 axis. Its activity is independent of pituitary stimulation, and its chronic signaling provides a continuous stimulus for hypertrophy that is not limited by endogenous growth hormone pulsatility or hepatic sensitivity.

IGF-1 LR3 is not approved for human use by the FDA or other major regulators. It is not a controlled substance in most jurisdictions but is sold as a research chemical. Marketing for human consumption is not legal.

Products sold outside of regulated pharmaceutical channels frequently suffer from poor purity, incorrect amino acid sequencing, or degradation into inactive fragments. Buyers should prioritize suppliers that provide independent, third-party verification through High-Performance Liquid Chromatography (HPLC) and mass spectrometry to confirm both the identity and concentration of the peptide.